Key takeaways
Rinvoq (upadacitinib) and Simponi (golimumab) are both used to treat inflammatory conditions, but they have some key differences. Rinvoq is a Janus kinase (JAK) inhibitor taken as a daily oral tablet, while Simponi is a monoclonal antibody given as a monthly injection. Rinvoq is used for a wider range of conditions, including various types of arthritis, eczema, ulcerative colitis, and Crohn's disease, whereas Simponi is used for different types of arthritis and ulcerative colitis. Both Rinvoq and Simponi are only available as a brand medication. Rinvoq comes as an oral tablet while Simponi comes in a prefilled syringe or autoinjector for easier use. Both medications can raise the risk of serious infections, but Rinvoq also has a risk of blood clots. Simponi, on the other hand, can cause heart failure and nervous system problems. Additionally, Rinvoq is not recommended during pregnancy, while the safety of Simponi during pregnancy is not well-studied.
